Amphotericin B-resistant Aspergillus flavus infection successfully treated with caspofungin, a novel antifungal agent

J Am Acad Dermatol. 2002 Jun;46(6):945-7. doi: 10.1067/mjd.2002.120627.

Abstract

Invasive aspergillosis is uncommon in immunocompetent hosts but is the second most common opportunistic fungal infection in immunocompromised patients. There has been a dramatic increase in the incidence of life-threatening aspergillosis during the past 2 decades, and the morbidity and mortality of these infections despite antifungal therapy remain unacceptably high. We describe a patient with amphotericin B-resistant Aspergillus flavus successfully treated with caspofungin, an agent belonging to a new class of antifungal drugs. Caspofungin shows great promise in the treatment of invasive aspergillosis.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Amphotericin B / pharmacology*
  • Anti-Bacterial Agents / therapeutic use*
  • Antifungal Agents / pharmacology*
  • Antifungal Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Arm
  • Aspergillosis / drug therapy*
  • Aspergillosis / pathology
  • Aspergillus flavus / drug effects*
  • Aspergillus flavus / isolation & purification
  • Caspofungin
  • Drug Resistance, Fungal*
  • Echinocandins
  • Female
  • Humans
  • Immunocompromised Host
  • Leukemia, Myeloid, Acute / drug therapy
  • Lipopeptides
  • Peptides*
  • Peptides, Cyclic*

Substances

  • Anti-Bacterial Agents
  • Antifungal Agents
  • Echinocandins
  • Lipopeptides
  • Peptides
  • Peptides, Cyclic
  • Amphotericin B
  • Caspofungin